Pamidronate Treatment of Osteonecrosis of the Hip in Young Male
A. Lo Gullo, R. Talotta, M. Atteritano*
Identifiers and Pagination:Year: 2018
First Page: 125
Last Page: 128
Publisher Id: TORJ-12-125
Article History:Received Date: 17/5/2018
Revision Received Date: 28/6/2018
Acceptance Date: 4/7/2018
Electronic publication date: 29/08/2018
Collection year: 2018
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: (https://creativecommons.org/licenses/by/4.0/legalcode). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Aseptic osteonecrosis of the hip is a clinical entity in which the necrotic process of the bone leads to pain and progressive disability.
Pamidronate seems to reduce drastically the activation of the osteoclasts so that it can be useful only in the early stage of the disease, delaying the time of bone collapsing.
A 27-years-old male was treated with pamidronate for three consecutive days every four weeks.
After three months the patient came back at control showing a marked improvement in clinical condition, referred full recover from pain and dysmotility with improvement of the quality of life, which was confirmed by the result of MRI he had for control.
We reported a case of aseptic osteonecrosis of the hip which was successfully treated pamidronate at dosage of 45 mg.